Key Points- Altimmune has begun enrolling its global Phase III PERFORMA trial of pemvidutide for MASH, with about 300 sites planned and 52-week data expected in 2029. The company is using AI-assisted pathology and expects its current cash to fund the program through that readout. -…This story appeared on finance.yahoo.com , 2026-08-12 14:05:03.